{
    "clinical_study": {
        "@rank": "62025", 
        "arm_group": [
            {
                "arm_group_label": "PBASE system 1.1 + CT100 (active treatment)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "PBASE system 1.1 + CT100 (placebo treatment)", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the performance of the PBASE system, in terms of\n      the efficacy of treatment in patients with idiopathic rhinitis."
        }, 
        "brief_title": "PBASE System Idiopathic Rhinitis Clinical Investigation", 
        "condition": "Idiopathic Rhinitis", 
        "condition_browse": {
            "mesh_term": "Rhinitis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with persistent (>12w) symptoms of idiopathic rhinitis dominated by nasal\n             congestion (\u00b1 secretion) for an average of at least 1 h per day for at least 5 days\n             during a period of 14 days\n\n          -  Having nasal congestion as major symptom, and a nasal congestion score of at least 2\n             (scale 0-3)\n\n          -  Male or female 18 - 65 years\n\n          -  Judged by the Investigator as suitable for participation in the study without safety\n             concerns based on medical history and physical examination.\n\n          -  Willing and able to provide written informed consent prior to participation in the\n             clinical investigation\n\n          -  Willing and able to comply with all study related procedures\n\n        Exclusion Criteria:\n\n          -  Patients with Allergic rhinitis, demonstrated by either positive skin prick test,\n             phadiatop or RAST\n\n          -  Ongoing respiratory tract infection including nasal cavity at inclusion (treatment\n             visit 1)\n\n          -  Systemic steroid treatment less than 4 weeks before the inclusion in the study\n\n          -  Patients with a history of nasal surgery like: septoplasty, cosmetic surgery, conchal\n             surgery or any other nasal surgery except closed reposition for nasal fracture\n\n          -  History of frequent nose bleeds or a condition that increases the risk of excessive\n             bleeding\n\n          -  Pronounced anterior septal deviation or other significant nasal pathology at\n             endoscopic examination\n\n          -  Current malignancy of any kind\n\n          -  Known allergy to polyvinylchloride or medicinal liquid paraffin\n\n          -  Any disease, condition (medical or surgical) which, in the opinion of the\n             investigator, might compromise the study results, or would place the subject at\n             increased risk.\n\n          -  Any implant with an electrical and/or neurostimulator device, including but not\n             limited to cardiac pacemaker, defibrillator, vagal neurostimulator, deep brain\n             stimulation, spinal stimulator, bone growth stimulator, or cochlear implant or any\n             other implant in the head-, and neck region.\n\n          -  Previous treated with radiation on the face, head or neck regions\n\n          -  Female patients who are pregnant or nursing, or become pregnant at any time from\n             inclusion of the study until end of the 8 week follow-up visit\n\n          -  Female patients: unwilling to use adequate contraceptive from the signing of the\n             informed consent until end of the 8 week follow-up visit\n\n          -  Received study drug in a clinical trial for an investigational drug within the\n             previous 30 days, or 5 half-lives, whichever is longer"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "208", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01844336", 
            "org_study_id": "PR003"
        }, 
        "intervention": [
            {
                "arm_group_label": "PBASE system 1.1 + CT100 (active treatment)", 
                "intervention_name": "PBASE system 1.1 + CT100 (active treatment)", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "PBASE system 1.1 + CT100 (placebo treatment)", 
                "intervention_name": "PBASE system 1.1 + CT100 (placebo treatment)", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 12, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Falun", 
                        "country": "Sweden"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gothenburg", 
                        "country": "Sweden"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lund", 
                        "country": "Sweden"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stockholm", 
                        "country": "Sweden"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "V\u00e4ster\u00e5s", 
                        "country": "Sweden"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "Sweden"
        }, 
        "number_of_arms": "2", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Sweden: Regional Ethical Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in total vasomotor rhinitis symptom score to visit 3", 
            "safety_issue": "No", 
            "time_frame": "From baseline to 28 days after treatment visit 1"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01844336"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Chordate Medical", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chordate Medical", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}